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Abstract
Premenstrual Dysphoric Disorder (PMDD) is a mood disorder affecting about 5% of women and is
associated with substantial morbidity. Albeit inconsistently, PMDD is described as being
characterized by heritable personality traits. Although PMDD is a heritable disorder, it is unclear
whether any of the heritable susceptibility to PMDD resides in heritable personality traits. In groups
of carefully characterized women with PMDD (n=68) and controls (n=56), we attempted to determine
whether diagnosis-related traits could be confirmed, as well as to determine whether such traits were
associated with SNPs in estrogen receptor alpha (ESR-1) that we previously demonstrated were
associated with PMDD. We observed 7/25 traits to be significantly different in patients and controls
and further showed that 11/12 significant associations observed between these 7 traits and 16 ESR-1
SNPs involved the intron 4 SNPs previously shown to be the locus of the association with PMDD.
While several interactions between genotype and diagnosis were observed, the effect of genotype in
most instances was in the same direction in patients and controls. These data demonstrate affective
state-independent personality traits that distinguish patients with PMDD from controls and further
support the relevance of ESR-1 polymorphic variants in the regulation of non-reproductive behaviors.
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Premenstrual Dysphoric Disorder (PMDD) is a disorder of affect dysregulation that affects
approximately 4–8% of women of reproductive age and is associated with degrees of morbidity
similar to those associated with major depression (Halbreich et al., 2003). Results from several
(but not all) (Payne et al., 2009) twin studies suggest that PMDD or, more specifically,
premenstrual syndrome (PMS – a diagnosis predating PMDD consisting of mood and/or
somatic symptoms confined to the luteal phase) is heritable, as are non-syndromal premenstrual
affective symptoms (Kendler et al., 1992); (Treloar et al., 2002); (Condon, 1993). Further, in
a previous study, we identified an association between PMDD and four intronic polymorphisms
in the estrogen receptor alpha (ESR-1) gene (Huo et al., 2007). Although the contribution of
specific genes to the variation in disorders like PMDD is likely to be small, many studies
suggest that the “deconstruction” of psychiatric illnesses into their symptomatic components
may identify endophenotypes that more clearly reflect the effects of common structural genetic
variants that contribute to the susceptibility to these disorders (Chan & Gottesman, 2008).
Indeed, several psychometric instruments (e.g. the Tridimensional Personality Questionnaire
(TPQ), which is described in the methods section) have been shown to identify factors that are
ostensibly heritable and likely to reflect genetic variance (Heath et al., 1994); (Zohar et al.,
2003). Thus, these tools may advance our efforts to identify the genetic contributions to
behavioral disorders.
Efforts to identify personality traits and personality disorders that are disproportionately
common among women with PMDD have yielded inconsistent results, perhaps consequent to
methodological confounds such as small sample sizes, lack of matched, healthy controls, and
presumptions that state-related symptoms were traits (Verri et al., 1997); (Freeman et al.,
1995); (Williams et al., 2007). Freeman et al. (1995) demonstrated elevated scores on all three
personality dimensions of the TPQ, particularly Harm Avoidance and Novelty Seeking, in
women with PMS compared with normative sample data; however, only 22% of PMS subjects
had high scores in more than one dimension, which suggests that no single pattern was strongly
characteristic of PMS subjects. Another study employing the TPQ and comparing PMDD
subjects with healthy controls found higher Harm Avoidance scores in the PMDD sample
(Verri et al., 1997). Other studies have also linked traits such as Neuroticism, Harm Avoidance,
and Novelty Seeking to women suffering from premenstrual mood disorders (e.g., PMS)
(Berlin et al., 2001); (Coppen & Kessel, 1963); (Freeman et al., 1995); (Taylor, 1979); (Gath
et al., 1987). As measured by the Personality Diagnostic Questionnaire-Revised (PDQ-R), the
“likelihood” or “possibility” of having a personality disorder was found to be significantly
higher in women with PMDD compared with asymptomatic controls in both the follicular and
luteal phases (thus implying trait rather than state-dependent differences) (Berlin et al.,
2001). Nonetheless, on several subscales, a diagnosis by phase interaction was found showing
a luteal phase-dependent increase in scores in PMDD subjects but not in asymptomatic controls
(Berlin et al., 2001).
Previous studies of heritability and genetic association have uncovered genetic links to PMDD.
The initial indication of heritability came not from studies of the syndrome PMDD or PMS
but rather from studies comparing the premenstrual symptoms of mothers and daughters and
those of monozygotic (MZ) vs. dizygotic (DZ) twins (Condon, 1993); (Kendler et al., 1992);
(Wilson et al., 1991). Wilson and colleagues found that daughters of mothers with self-reported
PMS were more likely to experience premenstrual symptoms than daughters of mothers
without PMS (1991). Two twin studies both found that correlations for MZ twins exceeded
those for DZ twins on most PMS subscale items (Condon, 1993); (Kendler et al., 1992).
Estimates of heritability for premenstrual symptoms range from 22%–37% and are as high as
43.3% for severe premenstrual symptoms (Kendler et al., 1992). Several genetic
polymorphisms have been tested for possible association with PMDD (Damberg et al., 2005);
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(Melke et al., 2003) including the following: three variants in the serotonin transporter
(SLC6A4), specifically the serotonin transporter gene-linked polymorphic region (5-
HTTLPR) (Heils et al., 1995), an intron 2 variable number of tandem repeats (VNTR) (Ogilvie
et al., 1996), and a G to T single nucleotide polymorphism (SNP) in the 3’ untranslated region
(UTR) (Battersby et al., 1999); an intron 2 VNTR in the gene for transcription factor activating
protein 2beta (AP-2beta) (Damberg et al., 2005); gene-based haplotypic variants in genes for
estrogen receptor alpha (ESR-1), estrogen receptor beta, and progesterone receptor (Huo et al.,
2007). We have previously reported a significant association between PMDD and ESR-1 (Huo
et al., 2007); significant associations have also been reported for serotonin receptor 1A
(Dhingra et al., 2007) and 5-HTTLPR (Praschak-Rieder et al., 2002).
Although both the heritability of PMDD and its association with personality traits have been
investigated, prior studies have not examined the relationship between genotypic variations
and personality traits in women with PMDD. As noted above, such studies might reveal genetic
influences in PMDD that are more closely expressed in component traits of the disorder. Studies
of associations between genetic variants and personality traits have been performed in non-
patient samples. For example, associations were reported between CYP2C19 and CYP2D6
polymorphisms and Harm Avoidance (Ishii et al., 2007); (Roberts et al., 2004). Additionally,
studies of genetic association with personality traits have been performed in affective disorders
other than PMDD. Findings include associations between Novelty Seeking, Harm Avoidance,
Self-Directedness and the T102C polymorphism of the 5-HT2A gene in women with social
anxiety disorder (SAD) (Lochner et al., 2007). Based on the previous research and the areas
where further study was necessary, we asked the following questions: 1) Can we identify
personality “traits” that differ in women with PMDD and controls? 2) Are these “traits”
associated with the SNPs in the estrogen receptor alpha gene (ESR-1) that we previously
identified as associated with PMDD? 3) Does the genetic variance in ESR-1 influence the
variance in the traits similarly in PMDD patients and controls?
Methods and Materials
Subjects and Recruitment Procedures
Our sample consisted of 68 women with PMDD and 56 normal, asymptomatic volunteers.
Women were recruited through newspaper advertisements. All participants were medication-
free. Women in both groups were similar in socioeconomic status and demographic
characteristics (years of education=17.1 +/− 3.26 vs. 16.0 +/− 2.03 in controls and patients,
respectively, t=1.56, p=ns). Prior to entering the study, prospective ratings were employed
using a daily visual analogue scale of self-ratings of affective symptoms (Rubinow et al.,
1984). Women in the PMDD group had to show at least a 30% increase in symptoms during
the luteal phase, adjusted for the range of the scale employed, for at least two of the three cycles
(Smith et al., 2003). All participants additionally met DSM-IV criteria for PMDD (Diagnostic
and Statistical Manual of Mental Disorders). Prospective ratings confirmed that women in the
control group showed no mood changes related to menstrual cycle phase. All subjects were
also administered a Structured Clinical Interview for DSM-IV (SCID) (Spitzer et al., 1990)
and a modified Schedule for Affective Disorders and Schizophrenia Lifetime (SADS-L)
(Spitzer & Endicott, 1979); women with PMDD were required to have no current or recent (<2
years) Axis I condition, and control women without PMDD were required to have no histories
of Axis I disorders. The two-year requirement eliminated subjects with PMDD with significant
current or recent comorbidities, which could serve as confounds, but did not eliminate the
majority of subjects with PMDD with more remote histories of an Axis I condition. All subjects
provided written informed consent, and the protocol was approved by the National Institute of
Mental Health Institutional Review Board. All subjects reported regular menstrual cycle
lengths, ranging between 21 to 33 days, and none had any significant medical illness within
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the previous year. Although all of the PMDD patients completed questionnaires in the follicular
phase, the controls did so in either the follicular or the luteal phase. In order to minimize genetic
variation, only Caucasian subjects were used for this analysis. Of the original sample, 40
PMDD and 33 control subjects had both personality and genetic data and were used in the
association analysis.
Genotyping
Genomic DNA was extracted from peripheral lymphocytes obtained from 20-ml of whole
blood with the Puregene DNA isolation kit (Gentra Systems, Minneapolis, Minnesota), used
according to the manufacturer’s instructions. Genotyping was performed by first amplifying
genomic DNA by PCR and then reading fluorescence intensity using the Prism 7900HT.
A total of 24 SNPs were selected from the Celera database and SNP database (dbSNP)
(http//www.ncbi.nlm.nih.gov/SNP/) to test for association of PMDD with estrogen receptor
alpha (ESR-1). A more detailed description of the analysis can be found in (Huo et al., 2007).
Personality Inventories
The NEO PI-R (Costa & McCrae, 1992) is a widely used 240-item, self-report questionnaire
that is based on decades of factor analytic research with adult populations and provides a
systematic assessment of emotional, interpersonal, experiential, attitudinal, and motivational
styles. Respondents are given five response choices for each item, ranging from strongly
disagree to strongly agree. There are 48 items for each of the five-factor model domain scales
including: Neuroticism, Extraversion, Openness, Agreeableness, and Contentiousness.
Internal consistency coefficients have ranged from 0.86 (Agreeableness) to 0.92 (Neuroticism),
and seven-year test-retest reliability coefficients ranged from 0.63 to 0.81 (Costa & McCrae,
1992). Cross-cultural and longitudinal studies have provided extensive empirical support for
the validity of the NEO (Costa & McCrae, 1988); (McCrae & Costa, 1997); (McCrae et al.,
1998).
The Tridimensional Personality Questionnaire (TPQ; (Cloninger et al., 1991)) is a 100-item
self-report questionnaire that assesses three personality dimensions -- Novelty Seeking,
Reward Dependence, and Harm Avoidance --each with four subscales. The dimensions
describe basic patterns of adaptive responses to specific classes of environmental stimuli.
Novelty Seeking is a tendency to respond strongly to novelty and cues for rewards that leads
to frequent exploration in pursuit of rewards and avoidance of punishment. For example, high
Novelty Seeking would reflect impulsiveness and disorderliness rather than reflection and
regimentation. Harm Avoidance is a tendency to respond strongly to aversive stimuli that leads
to learned inhibition of behavior in order to avoid punishment and novelty. For example, high
Harm Avoidance would reflect fear of uncertainty and shyness rather than confidence and
gregariousness. Reward Dependence is a tendency to maintain behaviors previously associated
with reward or relief of punishment and is proposed to be related to the brain systems involved
in behavioral maintenance. For example, high Reward Dependence would reflect
sentimentality and attachment rather than insensitiveness and detachment. Harm Avoidance is
broadly similar but not identical to other measures of neuroticism (Wetzel et al., 1992) that
have been previously associated with PMS (Ussher & Wilding, 1991); (Taylor et al., 1991);
(Hallman et al., 1987). Novelty seeking is similar to but not identical with the social dimension
of introversion-extraversion (Cloninger et al., 1991) or sensation seeking (McCourt et al.,
1993). The TPQ has been reported to be a valid and reliable measure based on normative data
from a United States national probability sample of 1019 adults (Cloninger et al., 1991). Alpha
coefficients for the TPQ scales in the female sample range from 0.61 to 0.85 and are consistent
across demographic groups; test-retest correlations range from 0.70 to 0.79 (Cloninger et al.,
1991).
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The 16-Personality Factors (16PF) is designed to measure normal personality traits and has
been widely used for more than 40 years for a variety of applications, including treatment
planning and counseling (Cattell, 1988); (Conn & Rieke, 1994). The questionnaire contains
sixteen bipolar scales (called "primary factors") and five global factors. The 16PF was chosen
because of its ability to measure sixteen independent dimensions that are associated with
personality: Warmth, Reasoning, Emotional Stability, Dominance, Liveliness, Rule-
Consciousness, Social Boldness, Sensitivity, Vigilance, Abstractedness, Privateness,
Apprehension, Openness to Change, Self-Reliance, Perfectionism, and Tension. Additionally,
the 16PF includes an Impression Management (IM) index that is used as an item-dependent
validity scale. IM, which can detect exaggeration of socially desirable responses, may also
serve as an index of the attempt to influences one’s image in the eyes of others. The stability
coefficients for the personality factors and validity scale range from r = 0.69 to r = 0.91 for 2
weeks, with the range of r = 0.56 to r = 0.82 for 2 months. The internal consistency of the
primary factors and validity scale ranged from [alpha] = 0.66 to [alpha] = 0.87 (Conn & Rieke,
1994).
Statistical Analysis
Statistical analyses were performed using SPSS (version 16.0, 2008). First, diagnostic group
differences on the 25 personality traits evaluated by the three scales were assessed using
analysis of variance (ANOVA). A total of seven out of twenty-five traits demonstrated
significant differences between controls and patients: Neuroticism, Extraversion, Emotional
Stability, Abstractedness, Apprehension, Impression Management, and Harm Avoidance. This
analysis was performed using the data from all subjects with personality trait data (68 PMDD
subjects, 56 controls). The subjects on whom both personality trait and genetic data were
obtained (40 PMDD subjects, 33 controls) were used to determine whether there was an effect
of genotype or diagnosis on the seven personality traits identified as distinguishing PMDD
subjects from controls. A multivariate General Linear Model (GLM) analysis was performed
for each SNP, with genotype and diagnosis as the independent factors and the personality traits
as the dependent factors. To ensure adequate numbers in each cell, genotypes containing a
minor allele (homozygous and heterozygous) were collapsed and compared with the
homozygous major allele genotype. A GLM also was performed to determine whether trait
scores differed as a function of menstrual phase in controls to ensure there was no phase
difference in personality traits. Another GLM was performed on PMDD subjects comparing
the personality scores of those with history of depression and those without to examine possible
confounding variables.
Results
As is consistent with previous research, no differences in personality scores were found
between those controls tested in the luteal phase and those tested in the follicular phase (Berlin
et al., 2001), thus justifying combining all scores for controls irrespective of phase of testing.
Seven of a total of 25 traits (across the three instruments used) demonstrated significant
differences between controls and patients: Neuroticism (F=21.69, p<0.001), Extraversion
(F=6.90, p<0.01), Emotional Stability (F=21.05, p<0.001), Abstractedness (F=7.62, p<0.01),
Apprehension (F=8.35, p<0.005), Harm Avoidance (F=12.04, p<0.001) and Impression
Management (in this study used as an index of social desirability). (F=8.42, p<0.005). To ensure
that these differences did not reflect a past history of depression (exclusionary in controls but
not patient subjects), a GLM comparing PMDD subjects with (n=23) and without (n=45) past
histories of depression was performed and demonstrated a significant effect for one of the seven
traits distinguishing patient subjects and controls (Apprehension (F=4.869, p< 0.031).
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Among these seven traits, twelve significant associations were observed with six of the sixteen
SNPs examined (see Table 1). Eleven of twelve of these associations included intron 4 SNPs
of ESR-1.
Genotypic associations revealed the following effects of the presence of a minor allele in
patients and controls: lower Emotional Stability (L0058), lower Impression Management
(L0058) (higher scores indicate a greater attempt to project a socially desirable image), higher
Harm Avoidance (L0026, L0060, L0061), higher Neuroticism (L0026), and higher
Abstractedness (L0025, L0026, L0060, L0061, L0055, L0058) (high scores reflect idea-
oriented, imaginative thinking while low scores reflect practical and concrete thinking) (F
values 4.0 –9.0, p’s< 0.01–0.05) (See Figure 1).
In addition, diagnosis-by-genotype interaction effects were found for four of the SNPs. In
patients but not controls, the presence of the minor allele was associated with the following:
decreased Emotional Stability (L0058 and L0025) (F=4.22, p<0.05; F=5.17, p<0.05,
respectively); and increased Neuroticism (L0060, L0023, and L0025) (F=4.47, p<0.05;
F=4.16, p<0.05; and F=4.76, p<0.05, respectively) (Figure 2).
Discussion
We identified seven psychological factors as more prominent in women with PMDD compared
with controls. Patients had greater scores on personality factors of Neuroticism,
Abstractedness, Apprehension, Harm Avoidance, while normal volunteers scored significantly
higher on Extraversion, Emotional Stability, and Impression Management. Notably, these
differences occurred despite patients completing the personality inventories in the follicular or
asymptomatic phase of the menstrual cycles. The validity of these trait differences is supported
by both the substantial sample sizes and, particularly, the careful characterization of the study
participants. Our data are consistent with earlier demonstrations of psychological trait scores
that distinguish PMDD patients from controls. Consistent with our findings, Ross and
colleagues found Neuroticism (NEO) accounted for a significant amount of variation in
premenstrual negative affect both before and after controlling for baseline (follicular) symptom
levels (2001), and Freeman and colleagues showed that PMS subjects scored significantly
higher on Harm Avoidance (as well as on Novelty Seeking and Reward Dependence) (1995).
More recently, Payne and colleagues found an association between high Openness (NEO)
scores and premenstrual mood symptoms (2009). Our findings similarly identified associations
with Neuroticism (NEO) and Harm Avoidance (TPQ) among others. Whether these “trait”
differences contribute to or are a consequence of PMDD, it is, nonetheless, clear that they are
enduring and not state-dependent (i.e. confined to the luteal phase).
While personality traits in PMDD subjects were assessed in the follicular phase, measures for
control subjects were obtained in both the follicular and luteal phases. To ensure that menstrual
phase was not a confounding variable, scores from controls taken in the follicular phase were
compared with those taken during the luteal phase. No significant differences were found
between the two phases. These results confirm the findings of Berlin (2001) that personality
traits do not differ with menstrual cycle phase in asymptomatic controls.
Our novel findings are the demonstration of significant associations between five of these
personality traits and previously identified polymorphic variants in ESR-1. Huo et al (2007)
found that four SNPs in intron 4 of ESR-1 distinguished between PMDD patients and controls
(L0025, L0060, L0061, L0026). An additional SNP (L0058) trended toward the separation of
patients from controls and was found to be in tight linkage disequilibrium with the other intron
4 SNPs, L0025, L0060, L0061, and L0026 (63%, 83%, 84%, and 74% respectively). Eleven
of the twelve associations that we observed with the psychological factors that distinguished
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PMDD patients from controls involved these intron 4 SNPs. Thus, the SNPs that are associated
with traits that are relevant for PMDD almost uniformly cluster in intron 4 of ESR-1. Both the
positive finding of associations between psychometric factors and SNPs associated with
PMDD, as well as the negative informational value of failure to find SNPs elsewhere in the
gene that associate with these psychometric traits, reinforce the results from our previous study
indicating the importance of intron 4 SNPs in PMDD.
These findings raise several questions. The first of these questions is whether both PMDD and
the traits that we assessed are heritable. Several twin studies strongly suggest that premenstrual
symptoms and PMS are heritable, with the heritability for severe premenstrual symptoms
estimated as high as 43% (Kendler et al., 1992); (Treloar et al., 2002); (Condon, 1993).
Additionally, genetic associations have been found between PMDD and polymorphic variants
of several genes: ESR-1, serotonin receptor 1A and 5-HTTLPR, the latter in women who also
had social anxiety disorder (Huo et al., 2007); (Dhingra et al., 2007); (Praschak-Rieder et al.,
2002).
Evidence for the heritability of psychological traits comes from several sources. Kandler and
colleagues found NEO personality traits to have higher correlations between MZ twins than
DZ twins, which suggests genetic influences (2009). A similar study of the TPQ scale found
that all scales of the test showed higher correlations for MZ pairs than for DZ pairs (Heath et
al., 1994). Finally, the TPQ trait of Harm Avoidance has a confirmed genetic linkage to locus
chromosome 8p21-3 (Cloninger et al., 1991); (Zohar et al., 2003). Thus, these findings together
with the diagnosis-related trait differences noted above indicate that these personality traits are
not only heritable but also exhibit significant differences between PMDD subjects and controls.
The second question is whether there is a basis for inferring that variation in estrogen receptor
signaling would contribute to different psychological properties of PMDD. Multiple
observations suggest the potential behavioral regulatory potency of ESR-1. These observations
include the following: 1) Estrogen regulates both blood flow and dopamine metabolism in the
prefrontal cortex, an area identified as critical in affective regulation (Berman et al., 1997);
(Keenan et al., 2001). 2) In rodents, the neurocircuitry that is selected to solve a specific
cognitive task varies as a function of estradiol levels (Zurkovsky et al., 2007). 3) In women
with PMDD, changes in estradiol levels have been demonstrated to precipitate affective
destabilization (Schmidt et al., 1998). Thus, estradiol-mediated signaling appears to play a
prominent role in the activation of neurocircuitry relevant to social cognition and affect
regulation.
Finally, are the associations we observed random or meaningful? We attempted to decrease
the number of associations that would appear significant by chance by interrogating one gene
(which we demonstrated as associated with PMDD) and only those psychological factors we
observed in a larger sample to distinguish patients and controls. When looking at the seven
traits and sixteen SNPs, approximately six associations would be expected to be found by
chance when using p=0.05 as a significance level, and these would be expected to have a
random distribution across the gene. However, our analysis found twelve significant genetic
interactions, and eleven out of twelve of the associations were found in the intron 4 SNPs.
These intron 4 SNPs were the same identified as being associated with PMDD or, in the case
of one SNP (L0058), in very close linkage disequilibrium with the associated SNPs. It therefore
seems unlikely that the significant trait associations that we observed are a product of chance.
It is worth noting, nonetheless, that the direction of the main effect of the SNP on the
psychological traits was not what we would have predicted from the comparative distribution
of major and minor alleles in women with PMDD and controls. In our previous study, the minor
alleles were invariably associated with controls and consequently appeared to serve a protective
function. Conversely, the minor alleles appear associated with increased symptomatic scores
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in both patients and controls. How might we reconcile the ostensibly contradictory findings
that ESR-1 is associated with PMDD and with four traits that characterize PMDD, but not in
the predictable direction?
The estrogen receptor alpha gene might influence behavioral expression in women with PMDD
in several ways: 1) by contributing to the regulation of behavioral traits that are relevant to
PMDD irrespective of diagnosis (i.e., same effect in patients and controls), and 2) by
influencing susceptibility to the development of PMDD. Thus, ESR-1 variants may, in concert
with other genes and environmental factors, predispose toward expression of certain traits, but
also may display epistasis with what are likely to be independent genetic factors to influence
the susceptibility toward steroid- regulated affective disorders. These findings indirectly
support Kendler’s demonstration that personality traits and PMDD are independently heritable
(Kendler et al., 1992). Thus, unlike Major Depression, in which much of the heritability may
reside in heritable personality (Kendler et al., 1992), PMDD displays heritability that is distinct
from the personality traits that may characterize women with this disorder.
A similar explanation could be adduced for the paradoxical interactive effects of diagnosis and
genotype on personality traits that we also observed, in which the presence of the minor allele
is associated with an increase in Neuroticism and a decrease in Emotional Stability in women
with PMDD and not controls. Thus, the effect of the gene differs in the two different
populations, a phenomenon reminiscent of the differing behavioral consequences of gene
knockout in male and female animals (Krezel et al., 2001). Considerable limitations
notwithstanding, these findings lend further support to the idea that reproductive steroids are
relevant to behavioral expression in asymptomatic women, as well as in women with
reproductive steroid-related mood disorders.
A significant limitation of our study is the small sample size (for genetic association studies).
Several steps were taken, however, to decrease the impact of this limitation. First, the sample
was diagnostically very well characterized, which decreases clinical heterogeneity. Second,
only polymorphisms in a gene already demonstrated to be significantly associated with PMDD
were examined. Third, the association analysis was restricted to behavioral traits that had
previously been found (in this study) to discriminate between patients and controls. Thus the
sample used was a purified sample with a priori reasons for looking at the clinical measures
and with both genetic variants and psychological factors that had been previously shown to
differ in patients and controls. The limited number of comparisons performed decreased the
likelihood that observed associations are the product of chance. Another potential limitation
is the association of a history of depression in PMDD patients with the trait of Apprehension;
however, this is the only association we found with a history of depression, and Apprehension
was not significantly associated with any of the SNPs. Nonetheless, the possibility that these
findings would differ if the history of depression were excluded can not be ruled out.
In conclusion, we have identified several personality traits that distinguish PMDD patients
from normal controls and that are predominantly associated with intron 4 SNPs in the estrogen
receptor alpha gene. These findings, while clearly preliminary, are instructive for several
reasons: 1) Genes coding for reproductive steroids, not surprisingly, are promising and
potentially potent sources of behavioral variance; 2) The decomposition of syndromes into
component processes – in this case personality traits – may be a superior strategy for identifying
the genetic contributions to affective disorders than examining the syndrome as a unitary
structure; 3) If personality traits in PMDD are heritable, then identification of profiles of traits
in larger samples might improve the resolution of our efforts to understand the contribution of
genetic factors to the susceptibility to experience PMDD.
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Error Bar: +/− 1 SE
Three sample comparisons of psychological traits in subjects homozygous for the major allele
(1/1) with those in whom a minor allele was present (1/2, 2/2) in patients with PMDD and
controls. Impression Management scores are lower in subjects carrying the minor allele in both
the PMDD and control samples (genotypic effect, F1=4.04, p=.05). The opposite effect is seen
with Abstractedness and Harm Avoidance (genotypic effects, F1=6.82, p=.01 and F1=6.77, p=.
01, respectively). In both samples, the subjects carrying the minor allele have higher scores
compared with those homozygous for the major allele in both the PMDD and control samples.
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Error Bar: +/− 1 SE
Two representative examples of the interaction effects between genotype and diagnosis
(PMDD vs controls) on psychological trait scores.
(A) Although the Emotional Stability scores of the controls do not change with genotype, the
PMDD subjects who are carrying the minor allele show decreased Emotional Stability scores
(F1=5.17, p=.03).
(B) A similar trend appears with Neuroticism. Control subjects maintain similar scores
regardless of allele, while PMDD subjects who carry the minor allele have increased
Neuroticism scores (F1=4.76, p=.03).
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